Skip to main content

Table 2 Clinical validity of QLU-C10D and FACT-8D (n = 308)

From: A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances

Instruments

Cancer stage

Number of patients

Mean (SD)

p-value

ES

RE

QLU-C10D

I/II

215

0.63 (0.19)

   
 

III/IV

93

0.51 (0.26)

<0.001

0.53

 

FACT-8D

I/II

215

0.65(0.18)

   
 

III/IV

93

0.55(0.25)

0.001

0.47

1.27

Instruments

OHA

Number of patients

Mean (SD)

p-value

ES

RE

QLU-C10D

Excellent/good

24

0.64 (0.22)

   
 

Fair/poor/very poor

284

0.29 (0.25)

<0.001

1.49

 

FACT-8D

Excellent/good

24

0.66(0.19)

   
 

Fair/poor/very poor

284

0.32(0.29)

<0.001

1.42

1.48

Instruments

ECOG

Number of patients

Mean (SD)

p-value

ES

RE

QLU-C10D

Grade 0/1

219

0.70 (0.18)

   
 

Grade 2–4

89

0.40 (0.23)

<0.001

1.46

 

FACT-8D

Grade 0/1

219

0.69(0.16)

   
 

Grade 2–4

89

0.49(0.27)

<0.001

0.93

2.45

Instruments

Mental health

Number of patients

Mean (SD)

p-value

ES

RE

QLU-C10D

Low risk/relatively low risk

187

0.71 (0.18)

   
 

Relatively high risk/high risk

121

0.47 (0.24)

<0.001

1.14

 

FACT-8D

Low risk/relatively low risk

187

0.73 (0.14)

   
 

Relatively high risk/high risk

121

0.48 (0.23)

<0.001

1.35

0.71

  1. ES: Effect size; RE: Relative efficiency; SD: Standard deviations
  2. Note: In the RE calculation, the denominator is the square of t-statistics for QLU-C10D, and the numerator is the square of t-statistics for FACT-8D. A RE value > 1 indicates superior clinical-groups validity for QLU-C10D, while a RE value < 1 suggests the opposite
  3. The analyses of cancer stage included only lymphoma and myeloma cases (N = 233), while all other analyses were based on the entire sample (N = 308)